Status:
COMPLETED
Changes in Serum antimüllerian Hormone Levels in Patients 3 and 12 Months After Endometrioma Sclerotherapy
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Endometriosis Ovary
Eligibility:
FEMALE
18-42 years
Phase:
NA
Brief Summary
Endometriosis affects 6-10% of women in childbearing age. It is a heterogeneous disease with three different forms: superficial endometriosis (peritoneal), ovarian endometrioma and deep pelvic endomet...
Eligibility Criteria
Inclusion
- Patient in childbearing age from 18 to 42 years.
- Patient with uni- or bilateral endometrioma(s) without clinical and ultrasound criteria for ovarian carcinoma.
- A sclerotherapy is programmed.
- Patient affiliated to a social security scheme.
- Patient who gave consent for this research.
Exclusion
- doubt about the endometriotic origin of the cyst
- suspect malignant ovarian disease.
- Pregnant or breastfeeding patient.
- Patient participating in other research with an exclusion period still in progress at the time of inclusion or those included in interventional research that interferes with the study protocol.
- Patient deprived of liberty by judicial or administrative decision.
- Patient (≥ 18 years old) under legal protection or unable to give consent.
- Patient does not speak French.
Key Trial Info
Start Date :
July 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2023
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04461899
Start Date
July 9 2020
End Date
April 14 2023
Last Update
September 25 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Femme Mère Enfant
Bron, France
2
Hopital de la Croix Rousse
Lyon, France, 69004
3
Hopital Lyon Sud
Pierre-Bénite, France, 69495